Form 13-F position report

REVANCE THERAPEUTICS INC

Reported by GEODE CAPITAL MANAGEMENT LLC

RVNC CUSIP 761330109 Manager CIK 0001214717

Reported 0 shares, down 2,297,582 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q1 2025
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 45 Through Q1 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 21413000
2022-03-31 26055000
2022-06-30 17094000
2022-09-30 37347000
2022-12-31 28325000
2023-03-31 51423738
2023-06-30 42913374
2023-09-30 20422402
2023-12-31 16917609
2024-03-31 9697712
2024-06-30 5907129
2024-09-30 11885465
2024-12-31 6986220
2025-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for REVANCE THERAPEUTICS INC held by GEODE CAPITAL MANAGEMENT LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2025 Reduced 0 -2,297,582 (-100.0%) 0 $0 2025-05-13
Q4 2024 Added 2,297,582 +7,928 (0.3%) < 0.01% $6,986,220 2025-02-12
Q3 2024 Reduced 2,289,654 -8,311 (-0.4%) < 0.01% $11,885,465 2024-11-12
Q2 2024 Added 2,297,965 +327,127 (16.6%) < 0.01% $5,907,129 2024-08-09
Q1 2024 Added 1,970,838 +46,417 (2.4%) < 0.01% $9,697,712 2024-05-13
Q4 2023 Added 1,924,421 +144,144 (8.1%) < 0.01% $16,917,609 2024-02-13
Q3 2023 Added 1,780,277 +84,767 (5.0%) < 0.01% $20,422,402 2023-11-13
Q2 2023 Added 1,695,510 +98,996 (6.2%) < 0.01% $42,913,374 2023-08-11
Q1 2023 Added 1,596,514 +62,069 (4.0%) < 0.01% $51,423,738 2023-05-15
Q4 2022 Added 1,534,445 +151,204 (10.9%) < 0.01% $28,325,000 2023-02-13
Q3 2022 Added 1,383,241 +146,289 (11.8%) < 0.01% $37,347,000 2022-11-14
Q2 2022 Reduced 1,236,952 -99,239 (-7.4%) < 0.01% $17,094,000 2022-08-12
Q1 2022 Added 1,336,191 +24,111 (1.8%) < 0.01% $26,055,000 2022-05-13
Q4 2021 Added 1,312,080 +107,692 (8.9%) < 0.01% $21,413,000 2022-02-11
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

171 managers reported REVANCE THERAPEUTICS INC for Q1 2025.

Managers reporting REVANCE THERAPEUTICS INC in Q1 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
DekaBank Deutsche Girozentrale Unchanged 86,100 0 < 0.01% $425,000 19 qtrs
IFP Advisors Inc Unchanged 0 0 < 0.01% $44 2 qtrs
BOOTHBAY FUND MANAGEMENT LLC Reduced 0 -13,477 0 $0 2 qtrs
JANUS HENDERSON GROUP PLC Reduced 0 -38,107 0 $0 14 qtrs
ALPINE ASSOCIATES MANAGEMENT INC Reduced 0 -2,349,966 0 $0 3 qtrs
STATE STREET CORPORATION Reduced 0 -2,439,140 0 $0 45 qtrs
CONCOURSE FINANCIAL GROUP SECURITIES INC Reduced 0 -570 0 $0 27 qtrs
SIGNATUREFD LLC Reduced 0 -235 0 $0 20 qtrs
Vanguard Personalized Indexing Management LLC Reduced 0 -15,056 0 $0 4 qtrs
Beryl Capital Management LLC Reduced 0 -5,935,009 0 $0 2 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2025
Filed
May 13, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.